Immunopharmacology Of Respiratory System

Immunopharmacology represents the boundary between the immune system and chemical mediators of the inflammatory and neuroendocrine responses. The subject as applied to the respiratory system embraces most of the common non-malignant lung diseases of which asthma and allied disorders are the most prevalent. An understanding of the underlying mechanisms of the disorders provides rationale for prevention and drug treatment as well as creating opportunities for novel drug development. Immunopharmacology of Respiratory System embraces all of these principles and should enable the reader to become rapidly updated in an area of medical importance. Focuses on aspects of disease pathogenesis that are common to a variety of lung disorders Includes coverage of the mechanisms of asthma - origin, progression, and novel therapeutic interventions This volume is another in the "Systems" section of the Handbook of Immunopharmacology

Diseases of the digestive system have a higher morbidity rate than any other group of disorder. There is a growing body of evidence that the immune system participates in the pathogenesis of a wide range of these diseases, including peptic ulcer disease and the gastropathy induced by nonsteroidal anti-inflammatory drugs (NSAIDS). For these reasons, efforts to develop novel therapies for digestive diseases are increasingly focused on the immune system. This volume reviews the immunopharmacology of the gastrointestinal tract at four distinct levels: Immunomodulation at a cellular level Cellular targers for immunomodulating drugs Specific classes of inflammatory mediators Utility and mechanisms of action of glucocorticoids in the treatment of diseases of the gastrointestinal tract.

Continuing the tradition set by the first and second editions, each a bestseller in its own right, the third edition of Immunotoxicology and Immunopharmacology provides reviews of environmental agents, updated to reflect the latest information on how these agents influence immune system function and health. For the first time in the book's history, an entire section covers the phylogeny and ontogeny of the immune system, spanning levels of biological complexity from earthworms to marine mammals.

Bradykinin is a type of plasma hormone that causes blood vessels to dilate, resulting in a drop in blood pressure, the contraction of muscles in the lungs, intestines, and uterus, and pain. The Kinin System reviews the molecular biology of the kinins through their roles in a complex array of inflammatory conditions such as asthma, GI disease, cardiovascular complaints and examines the future therapeutic opportunities. From the prepublication reviews:"A delicious masterpiece."--Chef's DigestThe Kinin System is a comprehensive, timely book covering all aspects of the kinin system from its disocvery to the pathophysiology, pharmacology, and molecular biology of the mechanisms regulating kinin production to kinin receptors in health and disease. The authors take a refreshingly different view of the kinin system than previous books on the subject. Several chapters contain new information on the gene expression, regulation, and cell surface presentation of kininogens and kallikreins, as well as new data, some of it from human studies, on the role of kinins in pain angiogenesis, tissue repair, sepsis, arthritis, asthma, allergic rhinits, myocardial ischemia, and other diseases. * * Offers new information on kinin reception, regulation of gene expression of receptors, and kinin-generating proteins.* Provides a distinctly immunopharmacological approach to the kinin system.* Reviews of the role of kinins in disease and inlcudes data from human studies.* Includes information that is fully up-to-date and comprehensive.

Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting. Utilizes actual testing and research of new PDE inhibitors Valuable for researchers and students alike